CGON
Neutral signalScored 2026-09-21 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
CG Oncology Inc.
- Nom
- CG Oncology Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $5.5B
- Employés
- 142
- PDG
- Arthur Kuan
- Site web
- https://cgoncology.com
- Marché
- IBRXURGN
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 2 000 titres (~134 630,00 $ US)
- Insiders
- POST LEONARD E
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$147,520
Avg sell (VWAP, 90d window) $73.76 vs last close $77.74 (+5.4%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$147,520 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-15
- Liquidity
- Liquid $62,108,189/day · 20d vol
- Last synced
-
2026-10-20 22:32:37
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | POST LEONARD E | Sell · S | 500 | $62.48 | $31,240 | Form 4 |
| 2026-09-15 | POST LEONARD E | Sell · S · 10b5-1 | 1,000 | $72.98 | $72,980 | Form 4 |
| 2026-08-14 | POST LEONARD E | Sell · S · 10b5-1 | 1,000 | $74.54 | $74,540 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-21 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
CGON presents a deeply unfavorable risk/reward profile: despite adequate liquidity, the company is burning cash rapidly with no visible path to profitability and severely negative profitability ratios across the board.
The first sentence of the analysis written for CGON on 2026-09-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 24.63 · operating margin -4722% — readings disagree
Suggested stop 70.63, nearest stored support minus 0.5 ATR(9.2% under the last close). Reward/risk to the next stored resistance is 2.88. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -15.0% | -7108.3% | -22327.5% | 92.1% | 99.9% | |
| Ebit Margin | -3985.0% | -7729.5% | -23827.0% | -18556.0% | -119.6% | |
| Ebitda Margin | -3949.3% | -7726.7% | -23818.6% | -18548.2% | -119.5% | |
| Operating Profit Margin | -4722.1% | -10067.3% | -27180.9% | -18453.4% | -121.7% | |
| Pretax Profit Margin | -3985.0% | -7729.5% | -23827.0% | -18556.5% | -124.0% | |
| Continuous Operations Profit Margin | -3985.0% | -7729.5% | -23827.0% | -18556.5% | -124.0% | |
| Net Profit Margin | -3985.0% | -7729.5% | -23827.0% | -18556.5% | -124.0% | |
| Bottom Line Profit Margin | -3985.0% | -7729.5% | -33234.3% | -22925.7% | -177.5% | |
| Current Ratio | 24.629 | 35.296 | 13.619 | 9.541 | 9.775 | |
| Quick Ratio | 24.579 | 35.296 | 13.619 | 9.541 | 9.775 | |
| Solvency Ratio | -4.092 | -4.109 | -3.348 | -1.570 | -0.696 | |
| Cash Ratio | 1.054 | 12.031 | 0.580 | 5.713 | 8.972 | |
| Price To Earnings Ratio | -19.962 | -20.340 | -36.441 | -56.318 | -132.750 | |
| Price To Earnings Growth Ratio | -0.420 | -0.532 | -0.668 | -0.415 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -0.420 | -0.532 | -0.668 | -0.415 | 0.000 | |
| Price To Earnings Diluted Ratio | -19.962 | -20.340 | -36.441 | -56.318 | -132.750 | |
| Price To Earnings Diluted Growth Ratio | -0.420 | -0.532 | -0.668 | -0.415 | 0.000 | |
| Price To Book Ratio | 4.265 | 2.444 | 13.404 | 19.787 | 61.534 | |
| Price To Sales Ratio | 794.465 | 1,573.666 | 12,141.517 | 12,967.903 | 239.126 | |
| Price To Free Cash Flow Ratio | -24.227 | -22.704 | -54.223 | -83.066 | -180.123 | |
| Price To Operating Cash Flow Ratio | -24.252 | -22.771 | -54.223 | -83.105 | -181.402 | |
| Debt To Assets Ratio | 0.009 | 0.000 | 0.005 | 0.108 | 0.258 | |
| Debt To Equity Ratio | 0.009 | 0.000 | 0.006 | 0.127 | 0.376 | |
| Debt To Capital Ratio | 0.009 | 0.000 | 0.006 | 0.113 | 0.273 | |
| Long Term Debt To Capital Ratio | 0.004 | 0.000 | 0.000 | 0.050 | 0.231 | |
| Financial Leverage Ratio | 1.052 | 1.029 | 1.079 | 1.180 | 1.458 | |
| Working Capital Turnover Ratio | 0.006 | 0.002 | 0.001 | 0.002 | 0.000 | |
| Operating Cash Flow Ratio | -4.292 | -3.684 | -3.205 | -1.932 | -2.285 | |
| Operating Cash Flow Sales Ratio | -32.759 | -69.107 | -223.917 | -156.042 | -1.318 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.003 | 1.000 | 1.000 | 1.007 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | -85.395 | -3.951 | -3.647 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -35,246.000 | -27.951 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -80.279 | -3.324 | -4.639 | |
| Operating Cash Flow Coverage Ratio | -18.850 | -330.727 | -44.349 | -1.869 | -0.903 | |
| Capital Expenditure Coverage Ratio | -987.657 | -336.380 | 0.000 | -2,128.857 | -140.763 | |
| Dividend Paid And Capex Coverage Ratio | -987.657 | -336.380 | 0.000 | -2,128.857 | -140.763 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -19.957 | -17.448 | -50.826 | -67.877 | -196.994 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -15.0% | ▲7093.2% | ▲5836.7% |
| Ebit Margin | -3985.0% | ▲3744.5% | ▲6858.4% |
| Ebitda Margin | -3949.3% | ▲3777.4% | ▲6883.2% |
| Operating Profit Margin | -4722.1% | ▲5345.1% | ▲7386.9% |
| Pretax Profit Margin | -3985.0% | ▲3744.5% | ▲6859.4% |
| Continuous Operations Profit Margin | -3985.0% | ▲3744.5% | ▲6859.4% |
| Net Profit Margin | -3985.0% | ▲3744.5% | ▲6859.4% |
| Bottom Line Profit Margin | -3985.0% | ▲3744.5% | ▲9625.4% |
| Current Ratio | 24.630 | ▼-10.667 | ▲6.057 |
| Quick Ratio | 24.579 | ▼-10.717 | ▲6.017 |
| Solvency Ratio | -4.092 | ▲0.017 | ▼-1.329 |
| Cash Ratio | 1.054 | ▼-10.977 | ▼-4.616 |
| Price To Earnings Ratio | -19.962 | ▲0.379 | ▲33.201 |
| Price To Earnings Growth Ratio | -0.420 | ▲0.112 | ▼-0.013 |
| Forward Price To Earnings Growth Ratio | -0.420 | ▲0.112 | ▼-0.013 |
| Price To Earnings Diluted Ratio | -19.962 | ▲0.379 | ▲33.201 |
| Price To Earnings Diluted Growth Ratio | -0.420 | ▲0.112 | ▼-0.013 |
| Price To Book Ratio | 4.265 | ▲1.821 | ▼-16.022 |
| Price To Sales Ratio | 794.465 | ▼-779.201 | ▼-4748.870 |
| Price To Free Cash Flow Ratio | -24.227 | ▼-1.523 | ▲48.641 |
| Price To Operating Cash Flow Ratio | -24.252 | ▼-1.480 | ▲48.899 |
| Debt To Assets Ratio | 0.009 | ▲0.009 | ▼-0.067 |
| Debt To Equity Ratio | 0.009 | ▲0.009 | ▼-0.094 |
| Debt To Capital Ratio | 0.009 | ▲0.009 | ▼-0.071 |
| Long Term Debt To Capital Ratio | 0.004 | ▲0.004 | ▼-0.053 |
| Financial Leverage Ratio | 1.052 | ▲0.023 | ▼-0.108 |
| Working Capital Turnover Ratio | 0.005 | ▲0.003 | ▲0.003 |
| Operating Cash Flow Ratio | -4.292 | ▼-0.608 | ▼-1.212 |
| Operating Cash Flow Sales Ratio | -32.759 | ▲36.348 | ▲63.870 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▼-0.002 | ▼-0.001 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲18.599 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲7054.790 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲17.649 |
| Operating Cash Flow Coverage Ratio | -18.850 | ▲311.877 | ▲60.489 |
| Capital Expenditure Coverage Ratio | -987.657 | ▼-651.276 | ▼-268.925 |
| Dividend Paid And Capex Coverage Ratio | -987.657 | ▼-651.276 | ▼-268.925 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -19.957 | ▼-2.509 | ▲50.663 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.21B | $1.79B | $2.48B | $2.48B | $2.48B | |
| Enterprise value | $3.18B | $1.54B | $2.47B | $2.40B | $2.44B | |
| EV / Sales | 788.16x | 1348.18x | 12106.05x | 12589.90x | 235.41x | |
| EV / Op. cash flow | -24.06x | -19.51x | -54.06x | -80.68x | -178.58x | |
| EV / Free cash flow | -24.04x | -19.45x | -54.06x | -80.64x | -177.32x | |
| EV / EBITDA | -19.96x | -17.45x | -50.83x | -67.88x | -196.99x | |
| Net debt / EBITDA | 0.16x | 2.92x | 0.15x | 2.04x | 3.11x | |
| Current ratio | 24.63x | 35.30x | 13.62x | 9.54x | 9.78x | |
| Income quality | 0.82x | 0.89x | 0.94x | 0.84x | 1.06x | |
| Graham net-net | $9 | $12 | $3 | $2 | $1 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 103.6% | |
| Working capital | $728.6M | $732.8M | $179.9M | $131.8M | $52.4M | |
| Invested capital | $759.1M | $733.3M | $180.4M | $132.3M | $52.6M | |
| Return on assets | -20.3% | -11.7% | -24.4% | -24.0% | -21.9% | |
| Operating ROA | -24.7% | -24.0% | -32.0% | -34.1% | 0.0% | |
| Return on tangible assets | -20.6% | -11.7% | -24.4% | -24.0% | -21.9% | |
| Return on equity | -21.4% | -12.0% | -26.3% | -28.3% | -31.9% | |
| Return on invested capital | -25.0% | -15.6% | -29.8% | -24.9% | -22.6% | |
| Return on capital employed | -25.1% | -15.6% | -30.0% | -26.6% | -23.9% | |
| Earnings yield | -5.0% | -4.9% | -2.0% | -1.4% | -0.5% | |
| Free cash flow yield | -4.1% | -4.4% | -1.8% | -1.2% | -0.6% | |
| Capex / Op. cash flow | -0.1% | -0.3% | 0.0% | -0.0% | -0.7% | |
| Capex / Depreciation | 9.3% | 731.3% | 0.0% | 93.3% | 970.0% | |
| Capex / Sales | 3.3% | 20.5% | 0.0% | 7.3% | 0.9% | |
| SG&A / Sales | 1820.0% | 2959.0% | 4853.4% | 3347.1% | 44.7% | |
| R&D / Sales | 2887.2% | 7208.3% | 22427.5% | 15198.4% | 176.9% | |
| Stock comp / Sales | 660.3% | 1001.1% | 749.0% | 353.9% | 10.7% | |
| Intangibles / Total assets | 1.4% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 62d | 250d | 165d | 579d | 0d | |
| Days payables outstanding | 449d | 29d | 26d | 23968d | 36610d | |
| Operating cycle | 185d | 250d | 165d | 579d | 0d | |
| Cash conversion cycle | -264d | 221d | 139d | -23389d | -36609d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-20 CG Oncology (NASDAQ:CGON) Director Leonard Post Sells 1,000 Shares of Stock CG Oncology, Inc. (NASDAQ: CGON - Get Free Report) Director Leonard Post sold 1,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $62.06, for a total transaction of $62,060.00. Following the completion of the sale, the director directly owned 1,000 shares in the company,
- 2026-10-13 CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical executive with more than 20 years of commercial leadership experience, Ms.
- 2026-10-12 Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC
- 2026-10-12 Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
- 2026-09-20 Insider Selling: CG Oncology (NASDAQ:CGON) Director Sells $72,980.00 in Stock CG Oncology, Inc. (NASDAQ: CGON - Get Free Report) Director Leonard Post sold 1,000 shares of the firm''s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $72.98, for a total transaction of $72,980.00. Following the completion of the sale, the director directly owned 1,000 shares
- 2026-09-14 CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-05 23,000 Shares in CG Oncology, Inc. $CGON Purchased by Jupiter Topco LLC Jupiter Topco LLC purchased a new stake in shares of CG Oncology, Inc. (NASDAQ: CGON) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,000 shares of the company''s stock, valued at approximately $1,634,000. Several other large investors have also recently
- 2026-09-02 15 Stocks to Watch With Short Squeeze Potential Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.
- 2026-09-02 CG Oncology to Present at Upcoming Investor Conferences in September DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:
- 2026-08-19 Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.